| 295) ound: Adherence to and the maintenance of treatment regimens are fundamental for pai |
| 296) Therefore, to design better treatment regimens for TB, we need to unde |
| 297) lled trials (RCTs) evaluating 5 different treatment regimens for genitourinary syndr |
| 298) All treatment regimens had comparable efficacy |
| 299) ettings for screening patients to improve treatment strategies in cervical cancer. |
| 300) or juxtaposing molecular subtype targeted treatment strategies with the adjuvant use |
| 301) and provides future insights for clinical treatment strategies. |
| 302) development of preclinical testing of new treatment strategies. |
| 303) Age, diet, disease state, and treatment adherence also influence drug re |
| 304) of interpersonal coordination to improve treatment adherence and reduce stigma, as |
| 305) oviral therapy and two explored issues of treatment adherence. |
| 306) osis and could help to develop an optimal treatment approach by an early detection. |
| 307) de effect profile of these AEDs, a recent treatment approach involves priority use o |
| 308) as the potential to inform a personalized treatment approach. |
| 309) Adropin treatment or transgenic adropin overexpres |
| 310) To date, there is no confirmed treatment or vaccine prevention strategy a |
| 311) today, there is no universal dengue fever treatment or vaccines unreservedly recomme |
| 312) f factors that are associated with poorer treatment outcome and inform the developme |
| 313) atment levels of perceived life stress on treatment outcome in a sample of 200 indiv |
| 314) ing blood is a significant factor for the treatment outcome in patients with locally |
| 315) udies published to date and difference in treatment protocols for TF-CBT used with p |
| 316) Development of treatment protocols specific to children w |
| 317) and caring and also on the use of medical treatment protocols. |
| 318) are an effective alternative to inpatient treatment that lead to sustained improveme |
| 319) For high-risk patients, the treatment that minimizes the risk of relap |
| 320) sent the hope for a new direction for HIV treatment that reduces adherence barriers |
| 321) Little is known about how the amount of treatment a person with aphasia receives i |
| 322) g signals for iron at 4 and 12 days after treatment, a significant decrease in peak |
| 323) physiology, pathophysiology, and disease treatment as they relate to gynecologic ma |
| 324) mbiont-free strain obtained by antibiotic treatment as well as genome analyses revea |
| 325) rofile followed by 2 weeks of either Epi treatment at 1 mg/kg/day by gavage (n = |
| 326) veloped for evaluating only one candidate treatment at a time, and are thus not opti |
| 327) he Bayesian posterior probability of each treatment being optimal. |
| |